Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DUT | P33316 | 4/20 | 0.56 |
| ▸ | P2RY2 | P41231 | 3/20 | 0.46 |
| ▸ | P2RY4 | P51582 | 2/20 | 0.46 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.46 |
| ▸ | UPP1 | Q16831 | 1/20 | 0.45 |
| ▸ | TYMS | P04818 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9811618 | 0.90 | DUT (0.61) | DUTP2RY2P2RY4P2RY6TYMS | |
| SCHEMBL9811623 | 0.90 | DUT (0.61) | DUTP2RY2P2RY4P2RY6TYMS | |
| SCHEMBL5709922 | 0.88 | UPP1 (0.57) | DUTP2RY2P2RY4P2RY6UPP1 | |
| SCHEMBL11201697 | 0.85 | DUT (0.60) | DUTP2RY2P2RY4P2RY6TYMS | |
| SCHEMBL5709916 | 0.84 | POLB (0.57) | — | |
| SCHEMBL9012072 | 0.84 | POLB (0.57) | — | |
| SCHEMBL9321645 | 0.84 | POLB (0.57) | — | |
| SCHEMBL9321729 | 0.84 | POLB (0.57) | — | |
| SCHEMBL1364671 | 0.84 | DUT (0.61) | DUTP2RY2P2RY4P2RY6TYMS | |
| SCHEMBL10763077 | 0.83 | TYMS (0.46) | TYMS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6822090-B2 | GENERATION OF PREFERENTIAL URIDINE DERIVATIVE; OBTAIN REACTION MIXTURE, EXPOSE TO TERTIARY AMINE, DEHYDRATING REACTANT AND AMMONIA, RECOVER CYTIDINE DERIVATIVE | MITSUI CHEMICALS, INC. (JP) | 2004-11-23 | — | — | US | disclosed |
| US-20030032797-A1 | Process for the preparation of cytidine derivatives | MITSUI CHEMICALS, INC. (JP) | 2003-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030032797-A1 | Process for the preparation of cytidine derivatives | CDA, DCTD, APOBEC3A | DUT 15/4885P2RY2 3374/4885P2RY4 2434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.